



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Onapgo (apomorphine) Page: 1 of 2

Effective Date: 5/14/2025 Last Review Date: 4/23/2025

Applies to: Illinois New Jersey Maryland
 Florida Kids Pennsylvania Kids Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Onapgo under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Onapgo is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Onapgo

Policy/Guideline:

Criteria for Initial Approval:

Parkinson's Disease

Authorization of 6 months may be granted for treatment of motor fluctuations in members with advanced Parkinson's disease when all of the following criteria are met:

- Member has clearly defined "on" periods.
- The member has "off" periods of at least 3 hours per day despite optimization efforts.
- The member must have had an inadequate response or intolerable adverse event with oral carbidopa/levodopa and one of the following anti-Parkinson agents:
 - Dopamine agonist (e.g., pramipexole, ropinirole)
 - Monoamine oxidase-B (MAO-B) inhibitor (e.g., selegiline, rasagiline)
 - Catechol-O-methyltransferase (COMT) inhibitor (e.g., entacapone, tolcapone)

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for advanced Parkinson's disease who have demonstrated a positive clinical response with the requested medication

Approval Duration and Quantity Restrictions:

Initial and Renewal Approval: 12 months

Quantity Level Limit: 30 cartridges (600mL) per 30 days



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Onapgo (apomorphine) Page: 2 of 2

Effective Date: 5/14/2025 Last Review Date: 4/23/2025

Applies to: Illinois New Jersey Maryland
 Florida Kids Pennsylvania Kids Virginia

References:

1. Onapgo [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.; February 2025.
2. National Institute for Health and Care Excellence (NICE) guideline: Parkinson’s disease in adults. Published July 19, 2017. Accessed February 12, 2025.
<https://www.nice.org.uk/guidance/ng71/resources/parkinsons-disease-in-adults-pdf-1837629189061>.